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A new section of the Journal of Translational Medicine is being introduced to encourage rapid communication of
methods and results that utilize computational modeling and epidemiologic approaches in translational medicine. The
focus will be on population-based studies that extend towards more molecular level analysis. Submission of studies
involving methods development is encouraged where actual application and results can be shown in the
healthcare and life sciences domains.Editorial
We introduce a new section of the Journal of Transla-
tional Medicine to encourage rapid communication of
methods and results that utilize computational modeling
and epidemiologic approaches in translational medicine.
The focus will be on population-based studies that ex-
tend towards more molecular level analysis. Submission
of studies involving methods development is encouraged
where actual application and results can be shown in the
healthcare and life sciences domains.
We acknowledge the “flood of data” emanating from
new technologies, e.g. genomic sequencing, but we must
also consider the enormity of data already existing in clin-
ical histories and observational studies, nationally and
internationally. There remains a critical need to re-focus
translational medicine on the clinical perspective, starting
with clinical need, to enhance the value of molecular-
based approaches. Both perspectives fundamentally drive
clinical utility and are very complementary and have been
discussed in editorials in this journal [1,2].
Ultimately translational medicine must improve patient
care and enhance patient-physician communication and
decision-making. Patients are complex biological systems
(processes) that evolve over time under the influence of
many factors, e.g. environmental, lifestyle, etc. that cause
an individual’s genomic risk to progress to disease. It is* Correspondence: m.liebman@strategicmedicine.com
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distribution, and reproduction in any mediumcritical to understand, represent, analyze and interpret
patients and disease, temporally, to acknowledge the com-
plexity of disease presentation, diagnosis and treatment
that go beyond genomic make-up. The successful integra-
tion of a more clinical/epidemiological base and one using
high throughput technology to develop high resolution,
but static, representation of a patient’s state is critical in
personalized and stratified medicine.
Genomic sequencing and gene expression analysis ap-
pear yield “quantitative” data for the bioinformatics com-
munity with little experience addressing clinical or
epidemiologic data. These last two are viewed as “softer”
or more “qualitative” but the reality of translational medi-
cine can only succeed these data sources approach a con-
tinuum rather than separable silos. Accurate diagnosis of a
patient is required to address stratification, disease sub-
typing, reliability of diagnostic criteria, physician compli-
ance with guidelines and different EHR’s and can limit the
correlation of molecular observation with clinical mani-
festation. Extending this correlation towards critical mech-
anistic understanding would become impossible. Medical
informatics has focused on immediate patient manage-
ment and does not necessarily address the comprehensive
data collection and data models necessary to support mo-
lecular studies and analysis.
Approaches to be highlighted in this section include:
1. Data-mining for health impact: The availability of
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opportunity to identify and extract patterns of
patient histories, pre-disease, at time of diagnosis,
response to treatment and treatment outcome that
can contribute to preventive and predictive
medicine and improved patient management. The
development of high quality data resources and the
advancement of methodologies to enable this data-
mining are important aspects in making these
activities translational. Additional development of
appropriate ontologies to represent the complex
knowledge necessary for translational research is
also critical [3].
2. Data modeling: Data-modeling is both a passive and
an active process. Conventional data modeling
creates models to link disparate data, with a
functional theme, e.g. disease progression:
pre-disease to outcome. Expanding this view, to
include a semantic data model, involves identifying
missing data elements critical to complete a
functional data model and supports the additional
collection of such data [4].
3. Health record system design: The success of
predictive approaches requires availability of
electronic documents generated when patient and
the health care infrastructure interact, including:
hospital stays, surgery records, drug prescriptions,
specialist health-care, death registries and EHR’s.
Data flows trace the pathological history of a patient
over time, and emphasize the evolution of diseases
[5].
4. Applications of epidemiologic analysis: The
patterns, causes, and effects of health and disease
conditions in defined populations form the
cornerstone of public health, and impacts policy
decisions and evidence-based medicine by
identifying risk factors for disease and targets for
preventive medicine [6].
5. Public policy evaluation: A critical aspect of
translational research is to reflect the impact of
public policy as well as to potentially effect its
development and implementation [7].
6. Hypothesis evaluation and testing: Robust and
comprehensive analysis of the fundamental
hypothesis of a study can identify early risks and
opportunities and optimize study design in both
clinical and observational studies [8].
7. Risk assessment in healthcare and life sciences: How
early can risk be detected? How can we identify,
prioritize and quantify the dimensions of risk (and
opportunity?) [9].
8. Measuring and correcting for effects of missing or
conflicting data: Methods to detect and potentially
correct, possibly through modeling/simulation,missing or conflicting data are critical to optimize
data analysis and interpretation [10].
9. Stratifying disease versus stratifying patients:
Clinical observations and patient history can
provide temporal portraits of disease that
complement genomic identification of risk and lead
to improved patient management [11].
10. Qualifying Data Content and quality: Important
data sources exist containing lifestyle and socio
cultural environment data, e.g. eating habits, socio-
economic situation, legal substance (tobacco,
alcohol and psychoactive drugs) use and illegal
substance use. These data sources include surveys.
Other important data may be Air Pollution Data
Sources, i.e. air quality data [12].
Submitted articles should describe how the approach
and results reflect the computational modeling and epi-
demiologic aspects of translational medicine derived
both from the richness of the data available (or to be
developed), and from the versatility of analysis method-
ologies, to contextually answer to the needs in:
 prevention (identification and evaluation of
modifiable risk factors)
 diagnosis (optimization of early detection,
stratification and staging)
 therapy (stratification of disease and personalization
of treatment)
 health offer planning (optimization of service
offerings based on volumes and health profiles of the
population)
 compliance (to clinical practice guidelines, to patient
behavior, to following physician orders)
 personalization (disease stratification based on
clinical presentation)
 patient management (integration of patient
stratification, e.g. genomics, disease stratification and
therapeutic options/outcomes)
 forecasts (predictive models for patient subgroups
for use in prevention, behavior modification, cost
estimation, etc.)
 public policy (relationship between policies and
public/patient/physician response; evidence for
opportunities to impact policy development)Competing interests
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